SAB BIOTHERAPEUTICS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
SAB BIOTHERAPEUTICS, INC. (SABS) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $4.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-05-12
- SAB BIOTHERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2026-03-31 was $4.00M, a 60.00% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2025-09-30 was $2.60M, a 18.18% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2025-06-30 was $2.00M, a 16.67% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2025-03-31 was $2.50M, a 13.64% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $8.60M, a 24.64% increase from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $6.90M, a 1.43% decline from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $7.00M, a 134.90% increase from fiscal 2021.
- SAB BIOTHERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2021 was $2.98M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 9 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|---|---|---|
| 2026-03-31 | $4.00M 10-Q · filed 2026-05-12 | |||
| 2025-09-30 | $2.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $4.60M derived: sum of 2 quarters · filed 2025-11-14 | $7.10M 10-Q · filed 2025-11-14 | $8.90M derived: sum of 4 quarters · filed 2026-03-09 |
| 2025-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $4.50M 10-Q · filed 2025-08-07 | $6.30M derived: sum of 3 quarters · filed 2026-03-09 | $8.50M derived: sum of 4 quarters · filed 2026-03-09 |
| 2025-03-31 | $2.50M 10-Q · filed 2025-05-09 | $4.30M derived: sum of 2 quarters · filed 2026-03-09 | $6.50M derived: sum of 3 quarters · filed 2026-03-09 | $8.90M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $4.00M derived: sum of 2 quarters · filed 2026-03-09 | $6.40M derived: sum of 3 quarters · filed 2026-03-09 | $8.60M 10-K · filed 2026-03-09 |
| 2024-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $4.60M derived: sum of 2 quarters · filed 2024-11-06 | $6.80M 10-Q · filed 2024-11-06 | $9.60M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | $2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.60M 10-Q · filed 2024-08-08 | $7.40M derived: sum of 3 quarters · filed 2025-03-31 | $8.60M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | $2.20M 10-Q · filed 2024-05-20 | $5.00M derived: sum of 2 quarters · filed 2025-03-31 | $6.20M derived: sum of 3 quarters · filed 2025-03-31 | $7.50M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $4.00M derived: sum of 2 quarters · filed 2025-03-31 | $5.30M derived: sum of 3 quarters · filed 2025-03-31 | $6.90M 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $2.50M derived: sum of 2 quarters · filed 2023-11-13 | $4.10M 10-Q · filed 2023-11-13 | $6.60M derived: sum of 4 quarters · filed 2024-03-29 |
| 2023-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $2.90M 10-Q · filed 2023-08-21 | $5.40M derived: sum of 3 quarters · filed 2024-03-29 | $7.00M derived: sum of 4 quarters · filed 2024-03-29 |
| 2023-03-31 | $1.60M 10-Q · filed 2023-05-15 | $4.10M derived: sum of 2 quarters · filed 2024-03-29 | $5.70M derived: sum of 3 quarters · filed 2024-03-29 | $7.00M derived: sum of 4 quarters · filed 2024-03-29 |
| 2022-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $4.10M derived: sum of 2 quarters · filed 2024-03-29 | $5.40M derived: sum of 3 quarters · filed 2024-03-29 | $7.00M 10-K · filed 2024-03-29 |
| 2022-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $2.90M derived: sum of 2 quarters · filed 2022-11-14 | $4.50M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $2.90M 10-Q · filed 2022-08-10 | ||
| 2022-03-31 | $1.60M 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $2.98M 10-K/A · filed 2023-04-28 | |||
| 2020-12-31 | -$4.23M 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |